Cormorant Asset Management LP 13D and 13G filings for EyePoint Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
2024-11-14 3:10 pm Purchase |
2024-09-30 | 13G | EyePoint Pharmaceuticals, Inc. EYPT |
Cormorant Asset Management LP | 8,325,000 12.200% |
2,286,765![]() (+37.87%) |
Filing |
2023-12-14 4:04 pm Purchase |
2023-12-04 | 13G | EyePoint Pharmaceuticals, Inc. EYPT |
Cormorant Asset Management LP | 6,038,235 12.360% |
6,038,235![]() (New Position) |
Filing |